ZYBERNO
Stock Report
Updated Sep 1, 2026

Grace Therapeutics, Inc. (GRCE)

Healthcare • NASDAQ

$2.13

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
18.0/100
POOR BUSINESS
Grace Therapeutics, Inc. (GRCE) scores 18/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-33.7%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.03x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-50.2%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Grace Therapeutics, Inc. (GRCE) stock report — Zyberno Score 18/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:2.13
Market Cap:$36.79M

Valuation Multiples (2)

P/B Ratio:0.76x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$24.28M

Price Action & Momentum (1)

% of 52-Week High:41.1%
B. Profitability Assessment

Return Metrics (5)

ROA:-32.1%
Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$55.19
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-275.6%
Latest Earnings Filed:2026-08-13
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:11.47x
Quick Ratio:11.47x
Cash Ratio:11.00x

Leverage Analysis (3)

Debt To Equity Ttm:0.03x
Debt-to-Equity Ratio:0.03x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:13,083,000.00
Cash And Cash Equivalents:13,756,000.00
Long Term Debt:$0.00
Net Debt:-$12.51M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$23.90M

Bottom Line Performance (3)

-$20.22M
Income Before Tax:-$21.92M
Ebitda Ttm:-23,897,000.00

Operating Expenses (5)

Operating Expenses:0.00
R And D Expense:2,147,000.00
Sga Expense:8,224,000.00
Income Tax Expense:-$1.70M
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$50.07M
Current Assets:$14.33M
Ppe Net:1,926,000.00
Goodwill:8,138,000.00
Intangible Assets:$27.60M

Liability Structure (4)

Total Liabilities:1,862,000.00
Current Liabilities:1,250,000.00
Long Term Debt:$0.00
Short Term Debt:$1.25M

Equity & Capital (3)

Equity:$48.21M
Retained Earnings:-$244.27M
Common Stock:100,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:1,250,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:105,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$10.29M$0.00

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:$0.00
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:7,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.17
-$1.17
Earnings Per Share Ttm:-$1.17

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$0.51

Book Value & Capital (2)

Book Value Per Share:$2.79
Cash Per Share:0.80

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-14.4%
C. Company Profile & Context

Corporate Information (6)

Symbol:GRCE
Company Name:Grace Therapeutics, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:17.27M
Shares Outstanding Basic:17.27M
Shares Outstanding Diluted:17.27M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 06:27:50 UTC
Data Timestamp:2026-08-20T17:29:45.363320
Scroll to Top